Answers are grounded in this paper and cite their sources.
Observational analysis found sustained treatment persistence and stable disease control in IBD patients, suggesting a viable long-term maintenance option.
Switching from intravenous to subcutaneous infliximab biosimilar CT-P13 was associated with sustained treatment persistence, stable disease control, favorable pharmacokinetics, and good tolerability over 3 years. These real-world findings support SC CT-P13 as a convenient long-term maintenance option in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Huguet et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: